EPA’s latest advances in non-animal methods signal a shift in how chemical safety evidence is generated and evaluated. Human airway tissue models and ingredient-based calculations offer alternatives for assessing specific surfactant and pesticide hazards. For businesses, the opportunity is not simply less testing, but better use of existing data and more targeted safety assessments. Understanding where these approaches apply and where further evidence is needed will be essential as regulatory expectations evolve.
What if improving chemical safety depended not on conducting more animal studies, but on asking better questions of human biology and existing data? On August 27, 2026, the U.S. Environmental Protection Agency (EPA) announced two scientific advances intended to move safety assessments in that direction. Focused on specific surfactant and pesticide evaluations, the approaches support EPA’s stated goal of eliminating mammalian animal testing by 2035 while maintaining protections for human health and the environment.
The significance extends beyond replacing one test with another. These developments reflect a broader shift in toxicology toward evidence that is more directly relevant to people. According to EPA, the approaches can help assess certain inhalation and oral hazards more efficiently and with greater human relevance. Their scope is specific: the announcement does not mean that animal testing has ended or that every chemical assessment can use the same alternatives.
Two developments illustrate what this shift looks like in practice:
- Modernized Surfactant Assessment
Surfactants help products such as soaps, detergents, and cleaners work effectively. Assessing whether these substances may irritate the respiratory system has traditionally involved animal studies. EPA’s updated framework uses three-dimensional (3D) human airway tissue models (laboratory-grown models made from human cells) to help predict how surfactants may affect the respiratory system.
EPA identifies several potential benefits of this human-based approach:
- More rapid data generation
- Greater relevance to human biological responses
- Less reliance on animal testing without compromising safety
The framework also allows reviewers to draw on existing scientific models to estimate potential risks rather than requiring new animal studies. The objective is to use the most appropriate evidence for the assessment, not simply to substitute tests without considering their relevance.
- Using the GHS Mixtures Equation for Certain Pesticides
The second advance uses the mixtures equation from the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) to estimate oral toxicity for certain pesticide formulations. It follows an analysis of nearly 700 pesticide formulations conducted with the National Institute of Environmental Health Sciences (NIEHS). According to EPA, the analysis showed that the equation can reliably identify formulations with little to no oral toxicity.
By using toxicity information already available for individual ingredients, the EPA can calculate the expected toxicity of certain formulated products without testing the final mixture on animals. This data-driven approach is expected to maintain scientific rigor while reducing unnecessary testing and accelerating regulatory reviews.
The Growing Role of New Approach Methodologies
Both developments sit within EPA’s broader use of new approach methodologies (NAMs). These are tools and strategies for evaluating chemical hazards that can reduce or replace animal testing in suitable contexts. Examples include computer modeling (in silico methods), cell-based studies (in vitro methods), and approaches that combine existing data to predict potential effects.
These methods are increasingly viewed as scientifically robust alternatives because they often provide results more quickly, at lower cost, and with greater relevance to human health outcomes than traditional animal studies. As computational power and biological modeling technologies continue to advance, NAMs are becoming an increasingly important component of the global regulatory framework.
From More Testing to Better Evidence
For industry, the deeper shift is from treating testing as a checklist to building an evidence strategy. The question is no longer simply which study to commission, but which combination of existing data, predictive tools, and targeted testing can answer the regulatory question convincingly. Future safety assessments are expected to rely more heavily on computational toxicology, human cell-based testing systems, and the use of existing scientific data to inform risk evaluations and regulatory decision-making.
Businesses with well-organized ingredient information and a clear understanding of their data gaps may be better positioned to use these approaches. Potential savings in In addition to reducing testing costs and timelines, these approaches can help generate data that may be more predictive of human health effects than conventional animal studies.
Looking Ahead
Reducing animal use is an important objective, but the broader opportunity is to improve how chemical safety is understood. EPA’s announcement points toward assessments that draw more effectively on human biology, computational science, and existing knowledge rather than relying on a single type of evidence.
Progress will depend on demonstrating where these methods work reliably and understanding where uncertainty remains. For businesses and regulators alike, the goal should be better-supported safety decisions, not fewer studies at any cost. As the adoption of NAMs continues to expand, the future of chemical and pesticide regulation is likely to be increasingly shaped by advanced modeling technologies, predictive science, and innovative testing methods that provide faster, more reliable, and more human-relevant insights into chemical safety.
What This Means for Businesses
These developments create an opportunity to reassess how safety data are generated and used, rather than assuming a new animal study is always the starting point. Businesses should consider where the announced approaches fit their products, what existing ingredient data can support an assessment, and which uncertainties still need to be addressed. Any expected cost or timeline benefits should remain conditional on scientific suitability and regulatory acceptance; EPA’s announcement is not a blanket exemption from testing requirements.
How H2 Compliance can help
- Toxicology and risk assessment support for chemical safety decisions.
- Regulatory strategy and market access planning.
- Regulatory tracking to identify changes affecting your portfolio.
- Hazard communication, including SDS authoring and labeling support.
Published November 2nd, 2026
Article image generated with the assistance of Artificial Intelligence.